Publications by authors named "Anders Fuglsang"

Claim this Profile
E
Evaluation of Incurred Subject Period Re-analysis (ISPR) as a Tool to Distinguish Fraudulent Pharmacokinetic Profile Pairs from Non-fraudulent Pairs.
Anders Fuglsang, Anshul Dogra, Naveen Sharma

AAPS J· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retron-Eco1 assembles NAD-hydrolyzing filaments that provide immunity against bacteriophages.
Arturo Carabias, Sarah Camara-Wilpert, Mario Rodríguez Mestre, Blanca Lopéz-Méndez, Ivo A Hendriks, Anders Fuglsang

Mol Cell· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conformational landscape of the type V-K CRISPR-associated transposon integration assembly.
Francisco Tenjo-Castaño, Nicholas Sofos, Luisa S Stutzke, Piero Temperini, Anders Fuglsang

Mol Cell· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure of the TnsB transposase-DNA complex of type V-K CRISPR-associated transposon.
Francisco Tenjo-Castaño, Nicholas Sofos, Blanca López-Méndez, Luisa S Stutzke, Anders Fuglsang

Nat Commun· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Professor Endrenyi's Legacy: An Evaluation of the Regulatory Requirement "Fixed Effects, Rather Than Random Effects, Should Be Used for All Terms".
Anders Fuglsang

J Pharm Pharm Sci· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intragenic codon usage in proteobacteria: Translational selection, IS expansion and genomic shrinkage.
Anders Fuglsang

Gene· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased Patient's Risk Associated with the Canadian Bioequivalence Guidance Due to Outlier Removal.
Anders Fuglsang

Ther Innov Regul Sci· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitigation of the convergence issues associated with semi-replicated bioequivalence data.
Anders Fuglsang

Pharm Stat· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Different Populations on Pharmacokinetic Bioequivalence Results: Can We Extrapolate Bioequivalence Results from One Population to Another?
Deniz Ozdin, Murray P Ducharme, France Varin, Anders Fuglsang, Dina Al-Numani

J Pharm Pharm Sci· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure of the mini-RNA-guided endonuclease CRISPR-Cas12j3.
Arturo Carabias, Anders Fuglsang, Piero Temperini, Tillmann Pape, Nicholas Sofos

Nat Commun· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of data manipulation in bioequivalence trials.
Anders Fuglsang

Eur J Pharm Sci· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural basis for inhibition of an archaeal CRISPR-Cas type I-D large subunit by an anti-CRISPR protein.
M Cemre Manav, Lan B Van, Jinzhong Lin, Anders Fuglsang, Xu Peng

Nat Commun· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA targeting by subtype I-D CRISPR-Cas shows type I and type III features.
Jinzhong Lin, Anders Fuglsang, Anders Lynge Kjeldsen, Kaiyan Sun, Yuvaraj Bhoobalan-Chitty

Nucleic Acids Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structures of the Cmr-β Complex Reveal the Regulation of the Immunity Mechanism of Type III-B CRISPR-Cas.
Nicholas Sofos, Mingxia Feng, Stefano Stella, Tillmann Pape, Anders Fuglsang

Mol Cell· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Three-Treatment Two-Stage Design for Selection of a Candidate Formulation and Subsequent Demonstration of Bioequivalence.
Anders Fuglsang

AAPS J· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reference Datasets for Studies in a Replicate Design Intended for Average Bioequivalence with Expanding Limits.
Helmut Schütz, Detlew Labes, Michael Tomashevskiy, Mario González-de la Parra, Anastasia Shitova, Anders Fuglsang

AAPS J· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highlights from the 2017 IPAC-RS/ISAM Joint Workshop "New Frontiers in Inhalation Technology".
Hugh D Smyth, Paul Colthorpe, Maureen George, Paul Jansen, Anders Fuglsang

J Aerosol Med Pulm Drug Deliv· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sample Size Estimation for the U.S. Food and Drug Administration's In Vitro Population Bioequivalence Test of DPIs, MDIs, Nasal Sprays, and Nebules.
Anders Fuglsang

J Aerosol Med Pulm Drug Deliv· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot and Repeat Trials as Development Tools Associated with Demonstration of Bioequivalence.
Anders Fuglsang

AAPS J· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reference datasets for bioequivalence trials in a two-group parallel design.
Anders Fuglsang, Helmut Schütz, Detlew Labes

AAPS J· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reference datasets for 2-treatment, 2-sequence, 2-period bioequivalence studies.
Helmut Schütz, Detlew Labes, Anders Fuglsang

AAPS J· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A sequential bioequivalence design with a potential ethical advantage.
Anders Fuglsang

AAPS J· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential bioequivalence approaches for parallel designs.
Anders Fuglsang

AAPS J· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Futility rules in bioequivalence trials with sequential designs.
Anders Fuglsang

AAPS J· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential bioequivalence trial designs with increased power and controlled type I error rates.
Anders Fuglsang

AAPS J· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis